1
Return

Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome-an analysis from RELAX-AHF

delete2014-10-07
delete127
delete
OA
AI
A
Adriaan A. Voors *
B
Beth A. Davison
J
John R. Teerlink
G
G. Michael Felker
G
Gad Cotter
F
Filippatos, Gerasimos
B
Barry Greenberg
P
Peter S. Pang
B
Bruce Levin
T
Tsushung A. Hua
T
Thomas Severin
P
Piotr Ponikowski
M
Marco Metra
DOI:10.1002/ejhf.170delete
deleteOriginal
deleteShare
deleteSave
View PDF
Abstract

Abstract

En 中文
AimsWe studied the characteristics and clinical outcome related to diuretic response and the effects of serelaxin in patients hospitalized for acute heart failure (AHF). Methods and resultsRELAX-AHF was a double-blind, placebo-controlled trial, enrolling 1161 patients admitted to hospital for AHF who were randomized to 48 h i.v infusions of placebo or serelaxin (30 mu g/kg per day) within 16 h from presentation. Diuretic response was defined as weight kg/[(total i.v. dose)/40 mg] + [(total oral dose)/80 mg)] furosemide (or equivalent loop diuretic dose) up to day 5. Median diuretic response was -0.42 (-1.00, -0.14) kg/40 mg. A poor diuretic response was independently associated with Western-like region (Western Europe, North America, Israel, and Poland), lower diastolic blood pressure, the absence of oedema, higher blood urea nitrogen, and lower levels of aspartate aminotransferase and potassium (all P < 0.01). Randomization to serelaxin was associated with lower doses of i.v. loop diuretics and slightly less weight loss, resulting in a neutral effect on diuretic response. Worse diuretic response was independently associated both with less relief of dyspnoea, measured with a visual analogue scale (VAS) at day 5 (primary endpoint; P = 0.0002), and with a higher risk of cardiovascular death or rehospitalization for heart failure or renal failure through day 60 (secondary endpoint, P < 0.0001), but not with increased 180-day cardiovascular mortality (P = 0.507). ConclusionsIn patients hospitalized for AHF, a poor diuretic response was associated with a poor in-hospital and early post-discharge clinical outcome. Serelaxin had a neutral effect on diuretic response. Trial registration: NCT00520806
Keywords:
Heart failure
Renal function
Diuretic response
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

European Journal of Heart Failure cover
European Journal of Heart Failure
IF:
10.8
Papers:
6.6K
Citations:
2.1W

Organization

U
university hospital attikon
Scholars:
5.2K
Papers: 3.5K
Citations: 5
D
Duke University
Scholars:
6.3W
Papers: 5.7W
Citations: 6.5W
C
Columbia University
Scholars:
7.1W
Papers: 6.4W
Citations: 263
U
university of california san francisco
Scholars:
5.2W
Papers: 4.0W
Citations: 67
N
Novartis
Scholars:
1.8W
Papers: 9.5K
Citations: 2.9K
University of California System cover
University of California System
Scholars:
37.2W
Papers: 33.6W
Citations: 6.6K
M
momentum research inc.
Scholars:
91
Papers: 157
Citations: 7
U
University of Groningen
Scholars:
4.4W
Papers: 4.3W
Citations: 5.9W
U
University of California San Diego
Scholars:
4.6W
Papers: 3.5W
Citations: 924
N
Northwestern University
Scholars:
6.1W
Papers: 5.2W
Citations: 3.9K
Cited Papers

Cited Papers

Citing Papers

Citing Papers